Inhibitors to Factor VIII: Treatment of Acute Bleeds

Négrier, Claude

doi:10.1002/9781118398258.ch11

Cited by 2 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the treatment of haemophilia patients with inhibitors, bypassing agents, such as recombinant activated factor VII (rFVIIa; NovoSeven ® , Novo Nordisk A/S, Bagsværd, Denmark) and activated prothrombin complex concentrates (APCC; FEIBA ® , Baxter International Inc., Deerfield, IL, USA), are generally used in acute bleeding and during surgery . These bypass FVIII and FIX, which are blocked by inhibitors, in the coagulation cascade . However, if the haemostatic effect of one bypassing agent is insufficient, the patients require another product or a combination of the two bypassing agents .…”

Section: Introductionmentioning

confidence: 99%

A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Despite this, FVIII is currently recommended by the Spanish Thrombosis and Haemostasis Society (SETH) for patients with low‐titre inhibitors and low responders (level of evidence IV) . Several formulae have been described in the literature to calculate an appropriate neutralising dose: 20 IU/kg for each BU of inhibitor , 40 × weight (kg) × BU , 2 × weight (kg) × [80 × (100–Hct]/100 × BU or a continuous infusion regimen of 100 IU/kg initially followed by 10 IU/kg/h .…”

Section: Resultsmentioning

confidence: 99%

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors

Mingot‐Castellano

Álvarez‐Román

López-Fernández

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

Introduction: Patients with severe haemophilia and inhibitors against factor VIII who require surgery need a prophylactic approach to prevent bleeding complications. Scientific evidence to decide the best prophylactic treatment is very limited and mainly based on retrospective or case series. Aims: To develop evidence-and expert opinion-based guidelines for prophylactic therapy for patients with haemophilia and inhibitors undergoing surgery. Methods: A panel of nine Spanish haematologists undertook a systematic review of the literature and selected publications providing relevant information regarding the prophylactic management of patients with haemophilia and inhibitors undergoing dental extraction, minor surgery or major surgery. Results: Although evidence is very limited, the panel considers that it seems advisable that prophylaxis should be given in most cases with a bypassing agent (aPCC or rFVIIa) and should start immediately before minor or major surgery. Patients should be closely monitored to enable dose/product modification as needed. Conclusion: It is necessary to communicate clinical experience in a detailed way in order to ensure optimal schemes of prophylaxis for patients with haemophilia and inhibitors. Development of objective outcomes to evaluate efficacy is crucial.

show abstract

Inhibitors to Factor VIII: Treatment of Acute Bleeds

Cited by 2 publications

References 49 publications

A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors

Contact Info

Product

Resources

About